McCray Andrew B.
Known title: EVP-CUOCIK: 0001777423
McCray Andrew B.'s purchase track record
McCray Andrew B. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/5/2022 | AMSF | $9K | -1.9% | +19.6% | -10.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AMSF | ▲ Buy | Grant | 3,540 | $0 | 6/7/2023 | View on chart |
| AMSF | ▼ Sell | Tax Withholding | 1,544 | $84K | 6/7/2023 | View on chart |
| AMSF | ▼ Sell | Open Market | 978 | $53K | 5/22/2023 | View on chart |
| AMSF | ▼ Sell | Open Market | 786 | $38K | 5/23/2022 | View on chart |
| AMSF | ▼ Sell | Open Market | 1,947 | $94K | 5/23/2022 | View on chart |
| AMSF | ▲ Buy | Grant | 3,894 | $0 | 5/19/2022 | View on chart |
| AMSF | ▲ Buy | Open Market | 200 | $9K | 5/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
AMERISAFE trades near 52-week low with low RSI
AMERISAFE stock is currently trading near its 52-week low, with an RSI of 22.5 suggesting the stock is in oversold territory. The company offers a dividend yield of 2.63% and a trailing P/E of 9.7, while the average analyst target price stands at $35.67. Recent news coverage did not contain specific updates regarding AMERISAFE, so this entry focuses on the current technical and fundamental positioning.
AMERISAFE trades near 52-week low with low RSI. AMERISAFE stock is currently trading near its 52-week low, with an RSI of 22.5 suggesting the stock is in oversold territory. The company offers a dividend yield of 2.63% and a trailing P/E of 9.7, while the average analyst target price stands at $35.67. Recent news coverage did not contain specific updates regarding AMERISAFE, so this entry focuses on the current technical and fundamental positioning.